Reata Pharma (RETA) Tops Q3 EPS by 74c

Reata Pharma (NASDAQ: RETA) reported Q3 EPS of ($1.47), $0.74 better than the analyst estimate of ($2.21). Revenue for the quarter came in at $540 thousand versus the consensus estimate of $1.03 million.

For earnings history and earnings-related data on Reata Pharma (RETA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c